← Return to all swing-trade opportunities
TMO — 20-Day Breakout with Volume
Status: Invalidated
Scanner score: 45.0/100
Why this was flagged
TMO was identified as a bullish technical setup based on the 20-Day Breakout with Volume pattern. The scanner found a score of 45.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner found Thermo Fisher Scientific Inc (TMO) because it is following a pattern called a 20-Day Breakout with Volume. This means the price moved above the highest point it reached in the last 20 days. Even more importantly, many more people were trading the stock than usual. The relative volume is 2.71 times higher than normal. This shows there is a lot of interest in the stock right now.
What the price plan means
The entry zone is between $572.39 and $576.68. If you enter here, the plan sets two targets for where the price might go: $623.84 and $649.56. To manage risk, there is a stop-loss at $546.67. A stop-loss is an automatic instruction to exit if the price drops too far. The reward-to-risk ratio is 2, which means the potential gain is twice as large as the potential loss.
What could make the idea fail
The stock's RSI is 71.28. RSI is a tool that measures how fast prices are moving. A high number like this can mean the stock is getting "overbought," which happens when people have bought too much too quickly. If the momentum slows down, the price could drop instead of hitting the targets.
Important reminder
This information is for educational purposes only and does not tell you what to do with your money.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (High confidence)
Thermo Fisher Scientific reported strong second-quarter 2026 financial results, characterized by a 10% revenue increase to $11.99 billion and an adjusted EPS of $6.03, both of which exceeded analyst estimates. The company demonstrated growth through organic revenue increases, new product launches, and strategic capital deployment, including the divestiture of its microbiology business and $1.0 billion in stock repurchases. Following these results, the stock outperformed the broader market during a negative trading session, and several analysts have raised their price targets.
Potentially supportive context
- Q2 2026 revenue reached $11.99 billion, surpassing analyst estimates.
- Adjusted EPS of $6.03 exceeded consensus expectations by 5.6%.
- Executed capital deployment via a $1.0 billion stock repurchase and business divestiture.
Risks and caution items
- Reported a decline in adjusted operating margin.
- Recent stock price volatility was previously influenced by lower outlooks from industry peers.
Latest reviewed article: Jul 23, 2026 6:08 pm
Recent related articles
Thermo Fisher Scientific reported strong second-quarter 2026 financial results, with revenue growing 10% to $11.99 billion and GAAP diluted EPS increasing 9% to $4.68. The company highlighted outstanding performance driven by its growth strategy, including the introduction of innovative new products and…
Shares of Thermo Fisher Scientific Inc. (TMO) rose 8.71% to $572.32 on Thursday, outperforming the broader market. This gain occurred during a generally negative trading session where the S&P 500 Index fell 1.21% and the Dow Jones Industrial Average dropped 0.97%. This…
Thermo Fisher Scientific (TMO) stock has climbed by over 10% following strong earnings and raised full-year guidance, leading analysts to issue bullish ratings and increase price targets. Deutsche Bank issued a "Catalyst Call: Buy" ahead of Q2 2026 earnings, citing overly negative…
Thermo Fisher Scientific reported robust Q2 2026 results with a 10% year-over-year revenue increase to $11.99 billion and a 5% organic revenue growth. Diluted GAAP EPS rose by 9% to $4.68, and adjusted EPS increased by 13% to $6.03. The company saw…
Thermo Fisher Scientific Inc. reported strong financial results for the second quarter and six months ended June 27, 2026. For the second quarter, sales increased to USD 11,994 million from USD 10,855 million year-over-year, with net income rising to USD 1,736 million.…
Thermo Fisher Scientific (TMO) saw its stock rebound by approximately 5% in premarket trading after reporting better-than-expected Q2 2026 results. This comes after a recent decline influenced by a peer's lower outlook. The life sciences company is based in Waltham, Massachusetts.
The article provides an earnings snapshot for Thermo Fisher's second quarter. However, the content appears to be missing, as only a privacy notice and image links are present. Therefore, no specific financial details or performance insights are available.
Thermo Fisher Scientific reported its second-quarter 2026 financial results, achieving $11.99 billion in revenue and an adjusted diluted EPS of $6.03. The company saw 5% organic revenue growth year-over-year and highlighted new product launches, strategic collaborations, and capital deployment actions, including stock…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Current volume is at least 1.25x the 20-day average volume.
- Price closed above the prior 20-day high with above-average volume.